<DOC>
	<DOCNO>NCT02731352</DOCNO>
	<brief_summary>The purpose study assess efficacy safety apatinib locally advanced 131I-refractory/resistant differentiate thyroid cancer</brief_summary>
	<brief_title>Study Apatinib Patients With Differentiated Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>1 . Locally advanced metastatic differentiate thyroid cancer ( papillary , follicular , Hurthle cell , poorly differentiate carcinoma ) . At least one measurable lesion ( helical CT scan long diameter ≥10mm , meet requirement standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1 ) ; 2 . Disease progression within 14 month inclusion ; 3 . Subjects must 131Irefractory / resistant define least one follow ; Lesions demonstrate iodine uptake radioiodine scan Subjects receive single radioactive iodine therapy within 12 month ( ≥ 3.7 Giga Bequerel（GBq） [ ≥ 100 millicurie（mCi） ] ) target lesion disease progression Every two radioactive iodine treatment interval &lt; 12 month , dose ≥ 3.7 GBq [ ≥100mCi ] , disease progress 12 month least iodine therapy ; Received total dose radioactive iodine therapy ≥ 22.2 GBq ( ≥ 600 mCi ) 4. main organ function normal ; 5 . Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :02 ; 6 . An expected survival ≥ 3 month ; 7 . Pregnancy test ( serum urine ) perform woman childbearing age within 7 day enrolment test result must negative . They shall take appropriate method contraception study 8th week post last administration study drug . For men , ( previous surgical sterilization accept ) , shall agree take appropriate method contraception study 8th week post last administration study drug ; 8 . Patient voluntarily join study sign Informed Consent Form study ; 1 . Other thyroid cancer histological subtypes ( medullary carcinoma , lymphoma sarcoma ) ; 2 . Received VEGFR inhibitor treatment within 6 month ; 3 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; Coronary heart disease great ClassII ; IIlevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class II cardiac dysfunction ; 4 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 5 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 3 month ; 6 . Abnormal Coagulation ( INR &gt; 1.5、APTT &gt; 1.5 UNL ) , tendency bleed ; 7 . Received antithyroid cancer chemotherapy treatment ( allow use lowdose chemotherapy radiation sensitizer ) thalidomide ( derivative ) therapy ; 8 . Pregnant lactating woman ; 9 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>